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Objective: The objective of this review is to provide an overview on the current development
of the speciﬁc reversal agents for Non-vitamin K Oral Anticoagulants (NOACs).
Methods: We conducted a systematic literature search strategy to identify potential studies
on Medline, Embase, and the Cochrane register.
Conclusions: These new reversal agents for NOACs, will help address the unmet need for the
management of major or life threatening bleeds, and the management of emergency
surgical procedures in patients taking NOACs. It will increase conﬁdence in the use of
NOACs; thereby extending treatment to a wider range of patients.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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At present, many Non-vitamin K Oral Anticoagulants (NOACs)
have become available for prophylaxis and treatment of
venous thromboembolism, and stroke prevention in atrial
ﬁbrillation patients as an alternative to vitamin K antagonist
(VKAs), such as warfarin and acenocoumarol. Though effec-
tive, VKAs pose critical challenges in clinical practice, such as
narrow therapeutic index, increased risk of intra cranial
hemorrhage (ICH) and slow onset and offset of action, which* Corresponding author.
E-mail address: jjdalal@hotmail.com (J. Dalal).
Abbreviations: NOAC, Non vitamin K Oral Anticoagulant; VKA, Vitam
Complex Concentrate.
http://dx.doi.org/10.1016/j.ihj.2015.11.023
0019-4832/# 2015 Cardiological Society of India. Published by Elsevierlimits their use in routine practice. Large clinical trials
evaluating the NOACs across the spectrum of thromboembolic
disorders have shown that they are at least as effective as
VKAs, with additional beneﬁt of reduced risk of ICH.3
An increased risk of bleeding is a known possible
complication of all anticoagulant therapies.4 A meta-analysis
by Wang & colleagues suggests that NOACs might be more
efﬁcacious and safe in Asians in comparison to non-Asians.5
Although the favorable efﬁcacy and safety proﬁle of all
NOACs has been demonstrated in the absence of a speciﬁc
reversal agent,3 certain clinical situations may arise in whichin K Antagonist; ICH, IntraCranial Hemorrhage; PCC, Prothrombin
 B.V. All rights reserved.
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short duration of action of the drugs, the discontinuation of
the drug is in most cases sufﬁcient to control the problem.
However, need for a reversal agent to neutralize these
compounds in case of an overdose or serious bleeding, or
when a rapid restoration of hemostasis is required (e.g.
perioperative period) has been acknowledged since the clinical
use of these anticoagulants began.
Adequate supportive care and temporary removal of all
antithrombotic drugs constitute the basis for management of
serious bleeding complications associated with NOACs.6 Pro-
hemostatic agents such as 3 or 4 factor prothrombin complex
concentrates (PCCs), and activated factor VII have been tried
for the NOAC-related bleeding with varying degrees of
success.6 Hemodialysis can remove up to 60% of circulating
dabigatran, while administration of activated charcoal may be
useful to reduce absorption of dabigatran if taken within 2 h of
ingestion and rivaroxaban or apixaban if taken within 6 h after
overdose or accidental ingestion.7–9
The following reversal agents for NOACs and other antic-
oagulants are currently in development.
Andexanet alfa (PRT064445) is a modiﬁed recombinant
derivative of factor Xa under development by Portola Phar-
maceuticals, Inc. as a reversal agent for all direct small
molecule FXa inhibitors (e.g. rivaroxaban, apixaban, edoxaban,
and betrixaban), LMWHs, and fondaparinux.10
Ciraparantag (PER977, previously known as aripazine), a
synthetic small molecule that binds to FXa inhibitors,
dabigatran, and heparins is being developed by Perosphere
Inc.11
Idarucizumab (BI655075), a humanized mouse monoclonal
antibody fragment (FAB), which binds to dabigatran with high
afﬁnity (Praxbind Injection, Boehringer Ingelheim Pharma-
ceuticals, Inc.).
2. Methods
We conducted a systematic literature search strategy to
identify potential studies on Medline (1950–present), Embase
(1980–present), and the Cochrane register for controlled trials
using OVID interface. Publications from potentially relevant
journals were also searched by hand.Table 1 – Pharmacological properties of reversal agents.
Idarucizumab17–19
Target Dabigatran FXa i
Mechanism of action Speciﬁc Humanized Fab:
speciﬁcally binds dabigatran
Non-
modi
comp
for di
Direct prothrombotic signals Absent Prese
Administration IV, bolus or short infusion IV, bo
infus
Re-initiate anticoagulation Possible No da
Inclusion criteria in patient trial Uncontrolled bleeding or
requiring emergency
surgery/procedure
Unco3. Study selection
Using structured search for idarucizumab (BI655075), andex-
anet alfa (PRT064445), and ciraparantag (PER977) the studies
were selected for this review.
4. The ideal reversal agent to an anticoagulant
The ideal reversal agent to an anticoagulant should be:
 Predictable and efﬁcacious
 Easy to use and with immediate action
 Sustained/Speciﬁc/Safe
5. Reversal agents for NOACs
Currently, three reversal agents for NOACs are in clinical
development: (1) idarucizumab, (2) andexanet alfa, (3) PER977
(Ciraparantag). Each of these differs in speciﬁcity, mechanism
of action, and the effect on recognized biomarkers of
anticoagulant activity. Table 1 summarizes the pharmacolog-
ical properties of these reversal agents.
5.1. Vitamin K
Vitamin K is frequently and misleadingly named an 'antidote'
for the VKAs. An important requirement for an 'reversal agent'
is to act rapidly, which is not the case with Vitamin K. When
Vitamin K is given to a patient taking a VKA, the liver uses the
Vitamin K to start producing fully functioning clotting factors.
However, restoring the coagulation factors that require
Vitamin K for their production is a slow and complex process
with variable effects among patients, which means that the
full effect is often not established before 24 h.12–14
It is important to remember that warfarin, with its variable
half-life of 20–60 h (dependent on individual patient char-
acteristics), still remains in the circulation as an active drug
after Vitamin K application. Thus, a re-dosing of Vitamin K
may become necessary, depending on the warfarin level andAndexanet alfa10 Aripazine (PER977)11
nhibitors Universal: FXa inhibitors, dabigatran,
and heparins
speciﬁc recombinant
ﬁed activated FX:
etitive afﬁnity
rect FXa inhibitors
Non-speciﬁc synthetic small molecule:
hydrogen bonds (NOACs);
charge–charge interactions (heparin)
nt (clinically not relevant) Absent
lus and/or continuous
ion
IV
ta available No data available
ntrolled bleeding only No patient trial yet
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severe bleeding, where rapid reversal is required, Vitamin K
needs to be combined with PCC.12–14
5.2. Andexanet alfa
Recombinant modiﬁed Factor Xa molecule is being developed
as a reversal agent for patients receiving a Factor Xa inhibitor,
who suffer a major bleeding episode or who may require
emergency surgery. It acts as a Factor Xa decoy that targets and
sequesters with high speciﬁcity both direct and indirect Factor
Xa inhibitors (NOACs: rivaroxaban, apixaban and edoxaban;
LMWH and fondaparinux) in the blood. Once bound with
andexanet alfa, the Factor Xa inhibitors are unable to bind to
and inhibit native Factor Xa, thus allowing for restoration of
normal hemostatic processes. Membrane-binding domain of
native FXa is deleted to decrease integration into the
prothrombinase complex to minimize the pro-thrombotic
effect. Unlike in the coagulation cascade with factor X,
andexanet alfa did not require any activation steps by factors
VIIa (from the extrinsic pathway) or IXa (from the intrinsic
pathway). The afﬁnity of FXa inhibitors to andexanet alfa and
native FXa is similar. Andexanet alfa is quickly and actively
eliminated (half-life 30–60 min).10 It does not exhibit detect-
able pro-coagulant or anticoagulant activity, as found in a
clotting assay examining the effects of rivaroxaban and
andexanet alfa on human plasma PT prolongation.10 Andex-
anet alfa dose-dependently reversed the inhibition of FXa by
direct FXa inhibitors and corrected the prolongation of ex vivo
clotting times by such inhibitors. Data are not yet available for
andexanet alfa in a patient setting, but data from healthy
volunteer studies have been published.
A proof-of-concept study, in healthy volunteers, the effect
of a continuous infusion of andexanet alfa was evaluated in
healthy volunteers (n = 144). Two minutes after completion of
the andexanet alfa intravenous bolus, mean anti FXa activity
decreased by >90% and was sustained throughout the infusion
period for both regimens ( p < 0.0001). For the 2-hour infusion
cohort, complete reversal of inhibition of thrombin generation
was sustained throughout the infusion and remained within
the normal range for 2 h post cessation of infusion. Andexanet
alfa was well tolerated with no serious or severe adverse
events. Anti-FXa activity appeared to return to similar levels as
in the placebo group within 2 h of the end of the andexanet alfa
infusion.15 Phase 3 studies to assess the effects of andexanet
alfa for reversal of anticoagulation with apixaban in healthy
elderly volunteers are ongoing.16
5.3. Idarucizumab
A humanized mouse monoclonal antibody fragment (FAB),
which binds to dabigatran with high afﬁnity (350 times higher
than that observed with native thrombin) and speciﬁcity.17–19
Idarucizumab potently binds to both free and thrombin-bound
dabigatran, thus neutralizing its activity.18,19 In ﬁrst-in-human
study, involving 110 healthy male volunteers aged between 18
and 45 years, the authors concluded that the pharmacokinetic
proﬁle of idarucizumab meets the requirement for rapid peak
exposure and rapid elimination, with no effect on pharmaco-
dynamic parameters. Idarucizumab was found to be safe andwell tolerated in healthy adult males.20 In another placebo-
controlled phase 1 trial, by Stephan Glund and colleagues, four
groups of healthy male volunteers were anticoagulated with
220 mg dabigatran twice daily for 3 days, and then on day 4,
they received an intravenous infusion of either placebo or 1–
4 g idarucizumab, 2 h after the last dabigatran dose (time to
peak plasma concentrations for dabigatran), or a 5 g dose 2 h
after dabigatran ingestion followed by an additional 2.5 g
idarucizumab after an hour. All idarucizumab doses immedi-
ately reversed the dabigatran effects in each clotting assay
studied (i.e., diluted thrombin time, ecarin clotting time,
activated partial thromboplastin time, thrombin time, and
activated clotting time). With 1 g idarucizumab the effect was
not sustained and anticoagulation effects reoccurred within 1–
10 h of infusion. Endogenous thrombin potential, which was
reduced by dabigatran, returned to normal values within
30 min after idarucizumab administration with doses of more
than 2 g. Similarly, ﬁbrin formation in blood from a standard-
ized forearm incision returned to normal values in a dose-
dependent manner.
In summary, shortly after administration of the reversal
agent, plasma concentrations of total dabigatran increased,
but without subsequent anticoagulant effects. This could be
explained by diffusion of unbound extravascular dabigatran
into the intravascular space, which is immediately bound by
idarucizumab and inactivated. Thus, idarucizumab also
eliminates dabigatran from tissue, followed by elimination
of the dabigatran–idarucizumab complex by the kidneys. Even
in patients with renal impairment, a reoccurrence of antic-
oagulation is not expected. The infusion of idarucizmab was
well tolerated by all volunteers, though minor drug-related
adverse events were reported in seven, but with no clinically
signiﬁcant difference in events between the groups.21,22
Currently, the safety and efﬁcacy of idarucizumab are being
evaluated in phase III Reversal Effects of Idarucizumab on Active
Dabigatran (RE-VERSE AD) clinical trial. The interim analysis of
90 patients who received idarucizumab authored by Pollack
et al. was published in NEJM on August 6, 2015. The study
included two groups of adults, 18 years of age or older, who were
taking dabigatran. The patients in group A (n = 51) presented
with overt, uncontrollable, or life-threatening bleeding that
was judged by the treating clinician to require a reversal agent,
whereas the patients in group B (n = 39) were those who required
an urgent surgical intervention or other invasive procedures
that could not be delayed for at least 8 h and for which normal
hemostasis was required. These inclusion criteria were chosen
to mirror the real world population in which the reversal agent
would be used. The eligible patients were given 5 g (total) of
intravenous idarucizumab as two 50 ml bolus infusions, each
containing 2.5 g of idarucizumab, not more than 15 min apart.
The primary end point was the maximum percentage reversal
of the anticoagulant effect of dabigatran, as determined at any
point from the end of the ﬁrst idarucizumab infusion up to 4 h
after the second infusion. This was assessed on the basis of the
measurement of the diluted thrombin time or ecarin clotting
time at a central laboratory. In this interim analysis, idaruci-
zumab normalized the test results in 88–98% of the patients
within minutes.
Hemostasis was restored at a median of 11.4 h in group A
patients (35 patients). Among 36 patients in group B who
Table 2 – Design of the andexanet alfa and RE-VERSE ADTM studies.
Andexanet alfa patient study15 RE-VERSE ADTM 23
Prospective, open-label design Prospective, open-label design
Estimated enrolment: 270 patients Estimated enrolment: 200–300 patients
Inclusion criteria:
 Patient taking a direct or indirect FXa inhibitor
 Acute bleeding (life-threatening or critical organ or drop in
hemoglobin (Hb) by ≥2 g/dL or below 8 g/dL)
Inclusion criteria:
 Patient taking dabigatran
 Requiring emergency surgery or procedures, or
 Uncontrolled bleeding, as deemed by the treating physician
Major exclusion criteria:
 Life-expectancy of <2 months from causes other than bleeding
 Patients expected to undergo surgery in <1 day
 Acute trauma where reversal of anticoagulation alone would
not be expected to control the acute bleeding
 History of a thrombotic event <1 month prior to screening
 Treatment with enoxaparin (<1 mg/kg/day) or anticipated use of
heparin within 24 h after andexanet alfa bolus
Exclusion criteria:
 Minor bleeds that can be managed with standard supportive care
 No clinical signs of bleeding
 Surgery of procedure that is elective, with a low risk of
uncontrolled or unmanageable bleeding, or that can be delayed for
≥8 h
Excludes patients, who are expected to receive other interventions,
such as PCC, FFP, or rFVIIa
No restrictions on use of FFP, PCC, aPCC, or rFVIIa
Primary endpoint: Proportion of patients with excellent or good
hemostasis (stopping major bleed at 24 h from the start of
andexanet alfa bolus)
Primary endpoint: Maximum reversal of dabigatran's activity,
based on central laboratory measurements of dTT or ECT from end
of ﬁrst infusion up to 4 h after completion of last infusion
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hemostasis was reported in 33, while mild and moderate
abnormality was reported in 2 patients and 1 patient,
respectively. One patient had a thrombotic event which
occurred within 72 h after idarucizumab administration.24
Table 2 highlights the differences in trial design for andexanet
alfa and idarucizumab studies.
In September 2015, the Committee for Medicinal Products
for Human Use (CHMP) adopted a positive opinion, recom-
mending the granting of a marketing authorization for the
medicinal product Praxbind (idarucizumab), a speciﬁc reversal
agent for dabigatran.24
In October 2015, the U.S. Food and Drug Administration
granted accelerated approval to idarucizumab (Praxbind
Injection, Boehringer Ingelheim Pharmaceuticals, Inc.) for
the treatment of patients on dabigatran, when reversal of
the anticoagulant effects is needed for emergency surgery/
urgent procedures, or in life-threatening or uncontrolled
bleeding.25
5.4. Ciraparantag
Ciraparantag (PER977) is a small (512 Da), synthetic, water-
soluble, cationic molecule designed to bind all the NOACs
(both F IIa and F Xa inhibitors) and heparins through
non-covalent hydrogen bonding and charge–charge interac-
tions. It prevents them from binding to their endogenous
targets and thus helps in reversing their anticoagulant
effect. Thus PER977 has the potential to be a universal
reversal agent to different classes of anticoagulants currently
available.
In rat model PER977 reversed the anticoagulant effect of all
four NOACs.26 In a phase I trial of 180 healthy volunteers,
ciraparantag administered at a dose of 100–300 mg, immedi-
ately reversed anticoagulation effects exhibited by higher
dose of edoxaban, which was sustained for next 24 h. No
evidence of a pro-thrombotic effect was seen as determined
by prothrombin fragment 1.2, D-dimer, or tissue factor
pathway inhibitor.276. Conclusion
Though NOACs have been proven to be safe and efﬁcacious in
their respective large phase 3 clinical trials, a proportion of at
risk patients are still not receiving anticoagulation therapy
because of fear of bleeding. This fear is present both with the
clinician and the patient. However, the need for reversal of an
anticoagulant is rare and the rapid offset of the NOACs
obviates the need for such an agent in most situations. Despite
that, reversal agents for the NOACs would beneﬁt the small
group of patients who require emergency surgery or inter-
ventions and those with life-threatening bleeds. These new
reversal agents may provide reassurance regarding managing
the risks of bleeding, and so extending treatment to a wider
range of patients.
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